NCT03423030View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

March 28, 2018

Study Completion Date

March 28, 2018

Conditions

TuberculosisTuberculosis, Pulmonary

Interventions

DRUG

PBTZ169 Formulation

PBTZ169 Formulation supplied as powder for oral solution

DRUG

Placebo

matching placebo supplied as powder for oral solution

DRUG

PBTZ169 NCP

PBTZ169 NCP supplied as powder for oral solution

Trial Locations (1)

1011

Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

All Listed Sponsors

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Innovative Medicines for Tuberculosis

OTHER

NCT03423030 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation | Biotech Hunter | Biotech Hunter